Status:

RECRUITING

Prognostic Value of Conization and Negative HPV After Conization in AIS and Early Stage Cervical Cancer

Lead Sponsor:

Rambam Health Care Campus

Conditions:

Cervix Cancer

HPV-Related Malignancy

Eligibility:

FEMALE

18-85 years

Brief Summary

In women with cervical cancer -Squamous cell carcinoma, Adeno carcinoma, Adeno-squamous carcinoma or AIS we want to examine prospectively: 1. Examine if negative HR-HPV after conization to the HR-HP...

Detailed Description

The treatment of invasive cervical cancer is tailored according to the FIGO recommendations. The standard treatment for women with early-stage, (IA2-IB1) cervical cancer is simple or Radical Hysterect...

Eligibility Criteria

Inclusion

  • Age Range: 18-85 years old Cervical cancer stage I B 2(Tumor up to 4 cm FIGO 2018) AIS HPV types before and after conization

Exclusion

  • Pregnant women under 18 years old. Women who refused to continue to be in study. Women that data about HPV types , final pathology or complication are missing.

Key Trial Info

Start Date :

July 26 2023

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

July 1 2028

Estimated Enrollment :

200 Patients enrolled

Trial Details

Trial ID

NCT06196190

Start Date

July 26 2023

End Date

July 1 2028

Last Update

January 9 2024

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Rambam Health Care Center

Haifa, Israel, 31906